Medlive Technology Co., Ltd. (2192) AI Stock Analysis

• Market Cap: HK$11.13B
• Dividend Yield: 1.95%
• Average Volume (3M): 3.99M
• Price to Earnings (P/E): 32.4
• Beta (1Y): 1.51
• Revenue Growth: 33.41%
• EPS Growth: 26.81%
• Country: HK
• Employees: 747
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Distribution
• EPS (TTM): 0.47
• Shares Outstanding: 732,876,000
• 10 Day Avg. Volume: 8,179,301
• 30 Day Avg. Volume: 3,990,512
• PEG Ratio: 0.32
• Price to Book (P/B): 1.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 77.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$13.50
• Price Target Upside: -11.07% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 77 Outperform
• Price Target: HK$17.00 ▲(11.99%Upside)

The stock's overall score reflects strong financial performance and positive technical indicators. The main risks are associated with its premium valuation and potential overbought technical status.

Medlive Technology Co., Ltd. Business Overview & Revenue Model

Company Description

Medlive Technology Co., Ltd. (2192) is a technology-driven company that specializes in providing healthcare information services. The company operates primarily in the medical and healthcare sectors, offering a comprehensive platform that includes medical knowledge databases, online medical education, and other professional medical services to healthcare professionals and institutions.

How the Company Makes Money

Medlive Technology Co., Ltd. generates revenue through various streams, primarily by offering subscription-based access to its comprehensive medical knowledge databases and online educational content. The company also earns income through partnerships with pharmaceutical companies and healthcare institutions, which may involve providing targeted advertising and promotional services. Additionally, Medlive may receive fees for offering tailored solutions and consulting services to its clients in the healthcare industry.

Medlive Technology Co., Ltd. Financial Statement Overview

Summary

Medlive Technology Co., Ltd. demonstrates robust financial performance with strong revenue growth, stable gross and net profit margins, and a solid balance sheet with low leverage. The company also maintains healthy cash flows, despite some variability in investment activities.

Income Statement

Medlive Technology Co., Ltd. demonstrates robust revenue growth, with Total Revenue increasing from 2019 to 2024. The Gross Profit Margin and Net Profit Margin have remained strong, reflecting stable and efficient cost management. Despite a decline in EBIT Margin from previous years, the EBITDA Margin remains healthy, indicating strong operational performance.

Balance Sheet

The company's Balance Sheet is solid with a high Equity Ratio, suggesting financial stability and low reliance on debt. The Debt-to-Equity Ratio is very low, indicative of minimal financial leverage. Return on Equity has shown a positive trend, highlighting effective use of shareholder funds.

Cash Flow

Cash flow analysis reveals consistent Free Cash Flow generation, with positive growth over time. The Operating Cash Flow to Net Income Ratio indicates strong cash-generating capability. However, fluctuations in Investing Cash Flow suggest potential volatility in investment activities.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
558.46M	412.00M	314.05M	284.44M	213.53M
	Gross Profit
327.22M	251.34M	212.74M	200.73M	156.24M
	EBIT
53.65M	77.76M	134.85M	70.33M	103.45M
	EBITDA
121.35M	262.86M	144.56M	76.61M	110.37M
	Net Income Common Stockholders
315.15M	242.30M	117.32M	40.62M	85.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.15B	4.40B	4.22B	3.91B	147.09M
	Total Assets
5.11B	4.89B	4.60B	4.12B	227.06M
	Total Debt
22.63M	8.19M	11.26M	13.17M	12.07M
	Net Debt
-3.82B	-4.35B	-4.18B	-3.87B	-135.02M
	Total Liabilities
253.56M	248.61M	171.31M	143.37M	75.64M
	Stockholders Equity
4.80B	4.60B	4.40B	3.95B	151.41M
Cash Flow		Free Cash Flow
87.44M	69.34M	69.70M	42.47M	110.42M
	Operating Cash Flow
108.32M	101.87M	77.19M	44.43M	111.05M
	Investing Cash Flow
111.02M	-634.95M	-3.59B	-50.54M	13.00K
	Financing Cash Flow
-197.89M	-133.13M	-22.38M	3.79B	-2.83M

Medlive Technology Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2192, the sentiment is Positive. The current price of 15.18 is above the 20-day moving average (MA) of 13.41, above the 50-day MA of 12.45, and above the 200-day MA of 10.45, indicating a bullish trend. The MACD of 1.01 indicates Negative momentum. The RSI at 62.52 is Neutral, neither overbought nor oversold. The STOCH value of 80.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2192.

Medlive Technology Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3690	79 Outperform	HK$844.38B	19.21	23.82%	―	19.20%	156.71%
2192	77 Outperform	HK$11.13B	32.39	6.72%	1.95%	33.41%	26.81%
2318	72 Outperform	$1.00T	6.84		7.49%	11.71%	37.04%
1177	66 Neutral	$98.90B	52.12	6.14%	1.09%	7.63%	-24.23%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
1833	51 Neutral	$17.53B	96.28	0.96%	―	1.01%	―
0993	24 Underperform	€1.36B	―		―	-74.76%	33.57%

Medlive Technology Co., Ltd. Corporate Events

Medlive Technology Co., Ltd. Successfully Concludes Annual General Meeting with Key Resolutions Passed

Medlive Technology Co., Ltd. held its Annual General Meeting on May 8, 2025, where all proposed resolutions were approved by shareholders. Key outcomes included the re-election of directors, the declaration of a final dividend for 2024, and the approval of mandates for share repurchase and issuance, indicating strong shareholder support and strategic direction for the company’s future operations.

Medlive Technology Announces 2025 AGM with Key Resolutions

Medlive Technology Co., Ltd. has announced its upcoming annual general meeting scheduled for May 8, 2025, where key resolutions will be considered. These include the approval of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks shareholder approval for share repurchase and issuance mandates, potentially impacting its capital structure and market operations.

Medlive Technology Reports Strong Financial Growth in 2024

Medlive Technology Co., Ltd. reported a significant financial performance for the year ending December 31, 2024, with a 35.5% increase in revenue compared to the previous year. The company’s strong growth in precision marketing and corporate solutions contributed to a 31.2% rise in profit, highlighting its robust market positioning and potential positive implications for stakeholders.

Medlive Technology Co., Ltd. Announces Final Dividend for 2024

Medlive Technology Co., Ltd. has announced a final cash dividend for the year ended December 31, 2024. The dividend is set at RMB 0.1366 per share, equivalent to HKD 0.148 per share, with an exchange rate of RMB 1 to HKD 1.0831. Shareholders’ approval is expected on May 8, 2025, and the payment date is scheduled for June 6, 2025. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders.

Medlive Technology Adjusts Acquisition Consideration for Beijing Focus

Medlive Technology Co., Ltd. announced an adjustment to the consideration for acquiring a 60% equity interest in Beijing Focus Innovation Technology Co., Ltd. The adjustment was made because the accumulated audited net profits of Beijing Focus did not meet the guaranteed profit target, leading to a reduction in the total consideration from RMB48,000,000 to RMB37,868,260. This adjustment impacts the payment distribution to the sellers and reflects the company’s strategic financial management in response to performance metrics.